Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Glycine-Proline-Glutamate analogs
14 evidence topics · 13 sources
Trofinetide: FDA-approved indication, formulations, and weight-based dosing
| Patient weight | Recommended dosage |
|---|---|
| 9 kg to less than 12 kg | “5,000 mg twice daily” |
| 12 kg to less than 20 kg | “6,000 mg twice daily” |
| 20 kg to less than 35 kg | “8,000 mg twice daily” |
| 35 kg to less than 50 kg | “10,000 mg twice daily” |
| 50 kg or more | “12,000 mg twice daily” |
Trofinetide: class and rationale as a glycine-proline-glutamate analog
“Trofinetide is a synthetic analog of glycine–proline–glutamate, the N-terminal tripeptide of the insulin-like growth factor 1 protein, and has demonstrated clinical benefit in phase 2 studies in Rett syndrome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
LAVENDER phase 3 trial: design and co-primary endpoints in the prescribing information
LAVENDER phase 3 trial: co-primary efficacy results at week 12
| Measure | Trofinetide (N=93) | Placebo (N=94) |
|---|---|---|
| RSBQ mean baseline score (SE) | “43.7 (1.21)” | “44.5 (1.26)” |
| RSBQ mean week 12 score (SE) | “39.9 (1.38)” | “42.8 (1.42)” |
| RSBQ LS mean change from baseline to week 12 (SE) | “-4.9 (0.94)” | “-1.7 (0.90)” |
| CGI-I mean week 12 score (SE) | “3.5 (0.08)” | “3.8 (0.06)” |
| Endpoint | Trofinetide-placebo treatment difference, LS mean (95% CI) | p-value |
|---|---|---|
| RSBQ total score change from baseline | “-3.2 (-5.7, -0.6)” | “0.018” |
| CGI-I score at week 12 | “-0.3 (-0.5, -0.1)” | “0.003” |
LAVENDER phase 3 trial: effect sizes, key secondary endpoint, and disposition
“For the coprimary efficacy endpoints, least squares mean (LSM) change from baseline to week 12 in the Rett Syndrome Behaviour Questionnaire for trofinetide versus placebo was −4.9 versus −1.7 (P = 0.0175; Cohen’s d effect size, 0.37), and LSM Clinical Global Impression–Improvement at week 12 was 3.5 versus 3.8 (P = 0.0030; effect size, 0.47).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the key secondary efficacy endpoint, LSM change from baseline to week 12 in the Communication and Symbolic Behavior Scales Developmental Profile Infant–Toddler Checklist Social Composite score was −0.1 versus −1.1 (P = 0.0064; effect size, 0.43).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“155 participants (82.9%) completed the study (trofinetide, n = 70 (75.3%); placebo, n = 85 (90.4%))” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eighteen participants withdrew due to a TEAE (trofinetide, n = 16 (17.2%); placebo, n = 2 (2.1%)), with diarrhea being the primary TEAE leading to discontinuation (trofinetide, n = 12 (12.9%))” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trofinetide: warnings for diarrhea, weight loss, and vomiting
LILAC open-label extension: 40-week safety and efficacy
“Females with Rett syndrome aged 5-21 years received open-label treatment with trofinetide for 40 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 154 participants were enrolled and treated with trofinetide in LILAC. The most common adverse events in LILAC were diarrhea (74.7%), vomiting (28.6%), and COVID-19 (11.0%). Diarrhea was the most common adverse event leading to treatment withdrawal (21.4%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The Rett Syndrome Behaviour Questionnaire mean score (standard error) improvement from the LAVENDER baseline to week 40 in LILAC was -7.3 (1.62) and -7.0 (1.61) for participants treated with trofinetide and placebo in LAVENDER, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
LILAC-2 open-label extension: 32-month safety and efficacy
“In total, 77 participants were enrolled in LILAC-2. The most common AEs were diarrhea (53.2%), COVID-19 (27.3%), and vomiting (19.5%). The mean (standard error [SE]) change in RSBQ score from LAVENDER baseline to week 104 of LILAC-2 was -11.8 (2.45).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most caregivers (96%; n = 24/25) were satisfied or very satisfied with the benefits of trofinetide.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
DAFFODIL open-label study: girls aged 2 to 4 years
“DAFFODIL was a phase 2/3, open-label study of trofinetide consisting of two treatment periods (12 weeks [period A] and ∼21 months [period B]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fifteen participants were enrolled. Overall, the most common TEAEs were diarrhea (80.0%) and vomiting (53.3%), which were mild or moderate in severity. Steady-state exposure at clinical doses fell within the target exposure range.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
LOTUS real-world study: dosing, caregiver-reported benefit, and diarrhea
“Overall, 227 caregivers participated in this follow‐up. The median trofinetide dose at week 1 was 36.0% of the target dose and increased to over 80% by week 10 onwards; 55.2% of patients took the full trofinetide recommended daily dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of diarrhea varied from weeks 1 to 12 (23%–50%) and months 4 to 12 (26%–38%); most reports of diarrhea were contained inside the patient's diaper.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Expert consensus: trofinetide as first-line therapy and titration
“Two rounds of assessments were completed by 25 respondents in each round, resulting in agreement ≥ 75% being reached across the final statement set. The consensus supports trofinetide as the standard of care for eligible patients with early initiation and an individualized approach to titration to maximize efficacy and tolerability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Agreement (88%–100%) across statements 1–2 and 5–7 supports trofinetide as first‐line therapy in the standard of care for eligible patients with RTT aged ≥ 2 years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To minimize the impact of side effects, this consensus supports initiation at 5–10 mL (1000–2000 mg) BID or 25%–50% of the recommended weight‐banded dose BID and then titrate carefully at 5 mL (1000 mg) increase every 1–2 weeks based on tolerance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Respondents supported maintaining treatment with trofinetide for at least 6 months post titration to determine efficacy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote